Medical Oncology, Journal Year: 2024, Volume and Issue: 42(1)
Published: Dec. 19, 2024
Language: Английский
Diagnostics, Journal Year: 2025, Volume and Issue: 15(3), P. 252 - 252
Published: Jan. 22, 2025
In recent years, novel findings have progressively and promisingly supported the potential role of Artificial intelligence (AI) in transforming management various neoplasms, including hepatocellular carcinoma (HCC). HCC represents most common primary liver cancer. Alarmingly, incidence is dramatically increasing worldwide due to simultaneous “pandemic” spreading metabolic dysfunction-associated steatotic disease (MASLD). MASLD currently constitutes leading cause chronic hepatic damage (steatosis steatohepatitis), fibrosis, cirrhosis, configuring a scenario where an onset has been reported even early stage. On other hand, serious plague, significantly burdening outcomes hepatitis B (HBV) C (HCV) virus-infected patients. Despite progress this cancer, overall prognosis for advanced-stage patients continues be poor, suggesting absolute need develop personalized healthcare strategies further. “cold war”, machine learning techniques neural networks are emerging as weapons, able identify patterns biomarkers that would normally escaped human observation. Using advanced algorithms, AI can analyze large volumes clinical data medical images (including routinely obtained ultrasound data) with elevated accuracy, facilitating diagnosis, improving performance predictive models, supporting multidisciplinary (oncologist, gastroenterologist, surgeon, radiologist) team opting best “tailored” individual treatment. Additionally, contribute enhancing effectiveness metabolomics–radiomics-based promoting identification specific HCC-pathogenetic molecules new targets realizing therapeutic regimens. era precision medicine, integrating into routine practice appears promising frontier, opening avenues cancer research
Language: Английский
Citations
2
Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 13
Published: Feb. 14, 2025
Background NASH-associated liver cancer (NALC) is a significant contributor to global mortality, closely linked the increasing prevalence of non-alcoholic fatty disease (NAFLD) and steatohepatitis (NASH). This study comprehensively examines burden NALC from 1990 2021. Methods used data Global Burden Disease (GBD) 2021 database analyze death age-standardized rates (ASDR) globally regionally We applied Joinpoint regression analysis assess temporal trends, calculating annual percent change (APC) average (AAPC). Decomposition was performed break down mortality changes into contributions population aging, growth, epidemiological changes. A frontier evaluate relationship between sociodemographic development using Socio-Demographic Index (SDI). Prediction deaths ASDR 2045 were estimated Nordpred model. Results From 2021, increased significantly, with rising 0.38 per 100,000 in 0.48 Age-specific revealed that peaked 65–69 age group for men 70–74 women. indicated growth most toll, followed by aging Frontier showed countries like Mongolia Gambia farthest frontier, while Morocco Ukraine closest. suggest increase compared larger rise among Conclusion Through this study, data-driven approach provided reduce NALC. Essential support public health prevention strategies offered, helping guide targeted government interventions. Trends across regions, countries, groups, genders have been analyzed, providing valuable insights formulation evidence-based policies aimed at mitigating impact worldwide.
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: March 28, 2025
Liver cancer, characterized by its insidious nature, aggressive invasiveness, and propensity for metastasis, has witnessed a sustained increase in both incidence mortality rates recent years, underscoring the urgent need innovative diagnostic therapeutic approaches. Emerging research indicates that CircRNAs (circular RNAs) are abundantly stably present within cells, with their expression levels closely associated progression of various malignancies, including hepatocellular carcinoma. In context liver cancer progression, circRNAs exhibit promising potential as highly sensitive biomarkers, offering novel avenues early detection, also function pivotal regulatory factors carcinogenic process. This study endeavors to elucidate biogenesis, functional roles, underlying mechanisms carcinoma, thereby providing fresh perspective on pathogenesis laying robust foundation development more precise effective tools strategies.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: May 2, 2025
Objective The purpose of this study was to analyze the research hotspots and future trends in field ferroptosis hepatocellular carcinoma past 10 years by using bibliometrics visualization software, provide reference for directions field. Methods Web Science database searched from January 1, 2012, October 30, 2024, annual publication volume, countries, institutions, journals, authors, references, keywords, other information were analyzed bibliometrics, VOSviewer, CiteSpace. Results A total 645 English articles 729 institutions 32 countries included study, with 4545 authors published 261 journals. In three years, 518 published, accounting 80.3%. China has most publications, followed United States. Frontiers Oncology had highest number papers (n=26), while Cell citations (n=1206). current mainly focuses on two aspects: one is mechanism explore new therapeutic targets, exploration methods, such as photodynamic therapy nanomaterials, order inhibit proliferation tumor cells, reduce drug resistance, enhance efficacy regulating ferroptosis, which may become a development trend. Conclusion recent there have been increasing studies association between carcinoma. This first comprehensive bibliometric provides reliable promotes its further development.
Language: Английский
Citations
0
Cells, Journal Year: 2024, Volume and Issue: 14(1), P. 15 - 15
Published: Dec. 26, 2024
Ubiquitin-conjugating enzyme E2 T (UBE2T) is a crucial in the ubiquitin-proteasome system (UPS), playing significant role ubiquitination of proteins and influencing wide range cellular processes, including proliferation, differentiation, apoptosis, invasion, metabolism. Its overexpression has been implicated various malignancies, such as lung adenocarcinoma, gastric cancer, pancreatic liver ovarian where it correlates strongly with disease progression. UBE2T facilitates tumorigenesis malignant behaviors by mediating essential functions DNA repair, cell cycle regulation, activation oncogenic signaling pathways. High levels expression are associated poor survival outcomes, highlighting its potential molecular biomarker for cancer prognosis. Increasing evidence suggests that acts an oncogene could serve promising therapeutic target treatment. This review aims to provide detailed overview UBE2T’s structure, functions, mechanisms involved progression well recent developments UBE2T-targeted inhibitors. Such insights may pave way novel strategies diagnosis treatment, enhancing our understanding biology supporting development innovative approaches.
Language: Английский
Citations
3
Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 11
Published: Jan. 10, 2025
Primary hepatic carcinosarcoma (HCS) is an extremely rare malignant tumor with carcinomatous and sarcomatous elements. Few reported cases of HCS exist, especially sufficient records to describe imaging pathological features, making the diagnosis, treatment, prognosis a significant challenge for physicians. Here, we report case spontaneous rupture as initial symptom in 77-year-old elderly male who was admitted right upper abdominal pain 8 days. The computed tomography enhancement scan revealed one intrahepatic mixed density massive, enhanced shadow located mainly outside liver. We performed hepatectomy segment 4 through laparotomy. postoperative pathology results demonstrated HCS. patient recovered smoothly discharged after surgery. However, experienced recurrence died 5 months This underscores importance identifying high-risk populations personalized treatment strategies cases.
Language: Английский
Citations
0
Liver International, Journal Year: 2025, Volume and Issue: 45(2)
Published: Jan. 22, 2025
ABSTRACT Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common cause of hepatocellular carcinoma (HCC). In this study, we combine metabolomic gene expression analysis to compare HCC tissues with non‐tumoural (NTT). Methods A non‐targeted strategy LC–MS was applied 52 pairs human MASLD‐HCC NTT separated into 2 groups according fibrosis severity F0F1‐F2 versus F3F4. The genes related de Novo lipogenesis (DNL) fatty acid oxidation (FAO) has been analysed by quantitative RT‐PCR and/or interrogation RNA‐seq datasets in 259 (MASLD‐HCC vs. VIRUS‐HCC). Results Metabolomic revealed that acylcarnitines were main discriminating metabolites when compared MASLD‐HCC‐F0F1‐F2 MASLD‐HCC‐F3F4 NTT. Based on these data, a panel 15 selected DNL FAO indicated there no difference between MASLD‐HCC. contrast same comparative aetiology HCC: VIRUS‐HCC showed both aetiologies shared upregulation involved DNL. However, five (HADHA, CRAT, CPT1, CPT2 PPARA) are upregulated exclusively This result indicates pathways simultaneously activated VIRUS‐HCC. Conclusions These results suggest that, involvement adaptive metabolic different depending HCC. Moreover, dogma simultaneous activation incompatible cancer would not apply
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: Feb. 20, 2025
This investigation aimed to create a new nomogram based on complement C3 forecast 1-, 3-, and 5-year overall survival (OS) rates in patients with early-stage hepatocellular carcinoma (HCC) exhibiting microvascular invasion (MVI) post-curative surgery. study encompassed 1234 treated resection at the Affiliated Cancer Hospital of Guangxi Medical University. The cohort for primary included 865 from December 2015 2019, while validation comprised 369 patients. Follow-ups were conducted regularly until 2024. Variables predicting identified using Cox regression analyses, these, was constructed. nomogram's accuracy assessed via time-dependent ROC curves, calibration curves KM curve analyses. Investigations C3, PT, presence cirrhosis, tumor capsule, MVI-M2 as distinct predictors HCC Based these findings, predictive constructed validated, estimating OS. efficacy validated through analyses each demonstrating positive outcomes. Additionally, analysis effectively separated patient populations into two prognostic risk categories within both cohorts. In conclusion, has been developed corroborated multivariate analysis, early stages following surgical resection. tool proven be more effective forecasting outcomes such
Language: Английский
Citations
0
International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2623 - 2643
Published: March 1, 2025
In recent years, nanobiotechnology, widely used in hepatoma, holds great promise for improving targeted hepatocarcinoma therapy. On account of the unique properties low toxicity, good tolerance, biocompatibility, and biodegradability new nanomaterials, a drug delivery system (TDDS) has been constructed, which can boost therapeutic effect hepatoma-targeted drugs, reduce minimize off target reactions by enhancing permeability retention (EPR) active targeting, thus existing liver cancer therapy strategies. Different nanoparticles have their own advantages disadvantages. They be loaded with multiple drugs on same nanoparticle also surface modified each other to achieve synergistic anti-tumor effects. This essay provides comprehensive overview current status hepatocarcinoma, nanoparticles' structure, disadvantages nanoparticle, application progress cancer. We hope provide basis future clinical hepatoma using nanotechnology.
Language: Английский
Citations
0
BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 28, 2025
Cholangiocyte phenotype hepatocellular carcinoma (HCC) is highly invasive. This study aims to develop and validate an optimal machine learning model predict cholangiocyte HCC based on T1 mapping gadoxetic acid-enhanced MRI implement individual applications via the Shapley Additive explanation (SHAP). We included 180 patients with histologically confirmed from two institutions. Clinical imaging features were screened for predicting using Least Absolute Shrinkage Selection Operator (LASSO) logistic regression analysis. Five models constructed these features. A Kaplan-Meier survival analysis compare prognostic differences between phenotype-positive groups classical (cholangiocyte phenotype-negative) groups, was conducted explore information of model. The most significant clinicoradiological features, including platelet-to-lymphocyte ratio (PLR), tumor capsule, target sign hepatobiliary phase (HBP), relaxation time 20 min (T1rt-20 min), selected construct prediction Finally, we eXtreme Gradient Boosting (XGBoost) as predictive model, which achieved AUCs 0.835, 0.830, 0.816 0.776 in training, internal validation, external prospective validation cohorts, respectively, visual SHAP, T1rt-20 made a contribution. Survival showed statistically difference relapse-free (RFS) institution I (hazard [HR] 1.994; 95% CI, 1.059-3.758; P = 0.027), construction XGBoost can be used stratify RFS according prognosis (HR, 1.986; 1.061-3.717; 0.029). utilizing demonstrates potential identifying HCC. Furthermore, personalized enhanced through application providing valuable insights support clinical decision-making processes.
Language: Английский
Citations
0